Fda Approval
Fda Approval - Related Videos
01:26
FDA Approved Drugs: Changes to Approved Drugs
0 Views •
2025
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
10:29
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
0 Views •
Cited by 83 •
2010
In this article, we examine the methodology and considerations relevant to the FDA approved depression treatment protocol using the Neuronetics NeuroStar TMS device.
05:05
Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
0 Views •
Cited by 95 •
2011
We describe a technique for labeling and tracking stem cells with FDA-approved, superparamagnetic iron oxide (SPIO), ferumoxytol (Feraheme). This cellular imaging technique that utilizes magnetic resonance (MR) imaging for visualization, is readily accessible for long-term monitoring and diagnosis of successful or unsuccessful stem cell engraftments in patients.
10:03
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
0 Views •
Cited by 24 •
2013
Rescue of recombinant arenaviruses from cloned cDNAs, an approach referred to as reverse genetics, allows researchers to investigate the role of specific viral gene products, as well as the contribution of their different specific domains and residues, to many different aspects of the biology of arenavirus. Likewise, reverse genetics techniques in FDA-approved cell lines (Vero) for vaccine development provides novel possibilities for the generation of effective and safe vaccines to combat human...
10:38
In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
0 Views •
Cited by 17 •
2016
The alkaline comet assay measures DNA strand breaks in eukaryotic cells. By adding an Endonuclease III or human 8-oxoguanine-DNA-N-glycosylase digestion step, the assay can efficiently detect oxidative DNA damage. We describe methods for using these assays to detect DNA damage in rat liver.
FAQs
The FDA evaluates whether the expected therapeutic benefits justify known and potential risks for the intended population. This assessment depends on the strength of laboratory, clinical, manufacturing, and labeling evidence rather than on effectiveness alone. The resulting decision is therefore population-specific, because an acceptable benefit-risk balance may depend on the condition being treated and the proposed use.
Proposed labeling translates the evidence reviewed by the FDA into instructions and safety information for clinical use. It defines the drug’s indications, dosing, and warnings, helping communicate how the product should be used and what risks require attention. Labeling also establishes a reference point for interpreting later safety reports and updating regulatory information.
Manufacturing controls provide evidence that a drug or biologic can be produced with consistent quality. They complement laboratory and clinical findings by addressing whether the marketed product reliably corresponds to the material evaluated during development. Without this quality information, evidence of safety and effectiveness would be harder to apply confidently to routine clinical use.
The review combines several evidence streams rather than relying on a single experiment. Laboratory studies contribute early scientific information, clinical trials evaluate effects in people, manufacturing controls address product quality, and proposed labeling organizes the intended uses, dosing, and warnings. Together, these sources support a benefit-risk judgment for the specified population and indication.
Approval does not end safety evaluation. Postmarket pharmacovigilance uses adverse-event reports and additional studies to identify uncommon effects, assess how the product performs in real-world use, and determine whether regulatory information should change. This continuing process can refine warnings, dosing information, or other labeling when new evidence alters understanding of the product’s risks.
For pharmacology, FDA approval connects drug effects and risks with evidence from laboratory studies, clinical trials, product quality assessment, and clinical labeling. It helps define the conditions under which pharmacologic information supports patient use, including the intended population, dosing, indications, and warnings. Postmarket evidence then extends pharmacologic evaluation beyond the original clinical development setting.